MarketWatch3d
Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors
The company said a Phase 3 trial showed that after 68 weeks, those who took CagriSema achieved a weight loss of 15.7%, compared with a weight loss of 3.1% for those taking a placebo. Tomi Kilgore ...
Morningstar4d
Ozempic parent's new weight-loss drug works better, but not quite good enough
New trial data showed CagriSema led to 'superior' weight loss, but at a rate much less than original expectations of 25% Shares of Novo Nordisk A/S were getting hit hard in early Monday trading ...
Monthly Prescribing Reference4d
Significant Weight Loss Observed With CagriSema in REDEFINE 2 Trial
CagriSema-treated patients achieved superior weight loss compared with those who received placebo. Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide 2.4mg and ...
Wall Street Journal3d
Novo Nordisk Stock Slides After Obesity Drug Trial Disappoints
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in rival Eli Lilly also sold off. Find out more: New trial data showed the ...
BioSpace10d
Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...